ArticleJournal of inflammation research2026
Identification of Serum BST1 as a Biomarker to Predict Coronary Artery Lesions in Children with Kawasaki Disease Based on 4D-DIA Quantitative Proteomics.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Kawasaki disease (KD) is a leading cause of acquired heart disease in children, with coronary artery lesions (CAL) as its most severe complication. This observational study aimed to investigate the expression of bone marrow stromal cell antigen-1 (BST1) in KD patients and its value for predicting CAL. Methods: Serum samples were collected from KD patients before intravenous immunoglobulin (IVIG) treatment and healthy controls (HC) in Xi'an Children's Hospital from July 2023 to August 2024. KD Patients were stratified into CAL and non-CAL (nCAL) groups based on echocardiography. In the discovery cohort (8 KD-CAL patients, 7 KD-nCAL patients, and 4 HC), Sera were analyzed via four-dimensional data-independent acquisition (4D-DIA) quantitative proteomics. Differentially expressed proteins (DEPs) were identified and analyzed for bioinformatics. In the validation cohort (35 KD-CAL patients, 61 KD-nCAL patients, and 30 HC), serum BST1 was validated by enzyme-linked immunosorbent assay (ELISA). Receiver operating characteristic (ROC) curve was constructed to assess the performance of BST1 in predicting CAL. Results: A total of 2575 proteins were identified by 4D-DIA proteomics, with 807 DEPs in nCAL vs HC and 883 DEPs in CAL vs HC. Compared to nCAL, 213 DEPs were identified in CAL patients, among which BST1 was significantly upregulated only in the CAL group. Functional analyses revealed enrichment in innate immune response, cell adhesion, RNA processing pathways, complement and coagulation cascades, extracellular exosomes, and cellular metabolism. ELISA confirmation showed elevated BST1 levels in CAL patients, which positively correlated with Z-scores. ROC analysis demonstrated high prognostic accuracy for CAL (AUC=0.9052). Conclusion: Serum BST1 has the potential to be a predictive biomarker for CAL in KD patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.